详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

ALCAM-EGFR Interaction Regulates Myelomagenesis.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Sichuan University, West China Hospital, China, Chengdu, China. [2]Sichuan university, Chengdu, Si, China. [3]Department of Hematology, West China Hospital/State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, chengdu, China. [4]Research Institute of Houston Methodist Hospital, Houston, Texas, United States. [5]Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. [6]State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, China. [7]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China. [8]Department of Pathology, West China Hospital, Sichuan University, China. [9]Sichuan University, West China Hospital, Chengdu, China. [10]University of California, San Francisco. [11]West Chian Hospital of Sichuan University. [12]Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, OH, US. [13]Department of Hematology, West China Hospital, Sichuan University, China. [14]Department of Hematology, West China Hospital/State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, Chengdu, China. [15]Sichuan University, West China Hospital. [16]Department of Oncology, West China Hospital, Sichuan University, China. [17]West China Hospital (Sichuan), Chengdu, Alabama, China. [18]West China Hospital of Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

摘要：

Multiple myeloma, a plasma cell malignancy in the bone marrow, remains largely incurable with currently available therapeutics. In this study, we discovered that the activated-leukocyte-cell-adhesion-molecule (ALCAM) interacted with epidermal growth factor receptor (EGFR), and regulated myelomagenesis. ALCAM was a negative regulator of myeloma clonogenicity. ALCAM expression was positively correlated with patients' survival. ALCAM-knockdown myeloma cells displayed enhanced colony formation in the presence of bone marrow stromal cells (BMSCs). BMSCs supported myeloma colony formation by secreted epidermal growth factor (EGF), which bound with its receptor (EGFR) on myeloma cells and activated Mek/Erk cell signaling, PI3K/Akt cell signaling and hedgehog pathway. ALCAM could also bind with EGFR, block EGF from binding to EGFR, and abolish EGFR-initiated cell signaling. Hence, our study identifies ALCAM as a novel negative regulator of myeloma pathogenesis.Copyright © 2021 American Society of Hematology.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 2 区血液学

最新[2023]版：

大类 | 1 区

医学

小类 | 2 区血液学

第一作者：

第一作者机构： [1]Sichuan University, West China Hospital, China, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [4]Research Institute of Houston Methodist Hospital, Houston, Texas, United States. [14]Department of Hematology, West China Hospital/State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, Chengdu, China. [*1]Department of Hematology, West China Hospital, and State Key Laboratory of Biotherapy and Cancer Center, Sichuan University,#37 GuoXue Xiang Street, Chengdu, China [*2]Center for Translational Research in HematologicalMalignancies, Cancer Center, Houston Methodist Hospital, Houston, TX, USA, 77030

推荐引用方式(GB/T 7714)：

APA：

MLA：